The chronic disease management market size was estimated at USD 6.31 billion in 2025 and is projected to increase from USD 7.02 billion in 2026 to approximately USD 18.56 billion by 2035, growing at a CAGR of 11.4% from 2026 to 2035. The chronic disease management market is driven by the increasing prevalence of chronic diseases, a growing geriatric population, and the expansion of telehealth, which provides convenient remote care options, improving patient outcomes and lowering costs.
Chronic disease management comprises the utilization of software, digital tools, and services to provide long-term care solutions, monitor patient health, and manage conditions, such as diabetes, cancer, and cardiovascular disorders. The market growth is driven by increasing demand for value-based care, which helps reduce hospitalizations and lower healthcare costs. Key applications include remote patient monitoring, telehealth services, and AI-driven predictive diagnostics, which enable early intervention and personalized treatment. Benefits include higher patient engagement, improved quality of life through better symptom control, and enhanced operational efficiency for healthcare providers.
Wearable health technology, such as continuous glucose monitors and smartwatches, tracking cardiovascular health, is becoming standard for continuous monitoring. These tools allow clinicians to monitor patients with chronic conditions, such as heart disease or diabetes, in real-time, shifting care from hospital settings to the home.
Healthcare providers are moving away from traditional fee-for-service models towards value-based care, which prioritizes patient outcomes and cost-effectiveness. This approach encourages the use of chronic disease management solutions that demonstrate reduced readmission rates and overall lower long-term care costs.
Telehealth has evolved from a pandemic-era tool into a mature, integrated component of routine chronic care management. Mobile health apps and virtual platforms are now seamlessly integrated with EHRs, improving communication between patients and providers and enhancing care coordination.
AI and ML are transforming the chronic disease management industry by shifting care from reactive to proactive, with health executives expanding significant value from these technologies. These technologies enable highly personalized, data-driven interventions for conditions like diabetes and cardiovascular disease by analyzing real-time data from remote patient monitoring (RPM) tools and wearable sensors. By identifying early risk signals and predicting disease progression, AI allows providers to intervene sooner, reducing hospitalizations and improving patient outcomes. Furthermore, ML algorithms streamline operational efficiency, easing the workload on clinical teams and allowing for scalable, personalized care management.
| Report Coverage | Details |
| Market Size in 2026 | USD 7.02 Billion |
| Market Size by 2035 | USD 18.56 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 11.4% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | By Type, By End-user, By Disease Type, By Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Agilent Technologies, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., HiMedia Laboratories Private Limited, Geno Technology, Inc., Illumina, Inc., Norgen Biotek Corp., New England Biolabs, Inc., Promega Corporation |
Driver
Increasing Prevalence of Chronic Disorders
The necessitating continuous, long-term care and monitoring. As the global aging population grows and lifestyle-related diseases become more common, the demand for proactive healthcare services to manage these lifelong conditions is surging. This rising burden is prompting healthcare payers and providers to adopt tech-enabled solutions, including remote monitoring and AI-driven platforms, to improve patient outcomes and minimize hospitalizations.
High Cost Of Implementation
The market growth is hindered by the high cost of implementation, encompassing significant initial investments in advanced technology, EHR integration, and staff training, which acts as a major barrier to the adoption of chronic disease management solutions, especially for smaller healthcare practices and providers in resource-limited regions.
Expansion of Digital Therapeutics
The offering of evidence-based, software-driven interventions that provide personalized, 24/7 care for conditions such as diabetes and hypertension. By leveraging AI and remote monitoring, these tools enable proactive self-management and continuous data tracking, allowing healthcare providers to shift from reactive, episodic care to sustained, preventive management. This digital shift enhances patient engagement and improves clinical outcomes, driving down overall healthcare costs and boosting demand for integrated digital solutions.
Why Did the Solutions Segment Hold a 58% Share for the Chronic Disease Management Market?
The solutions segment held a dominant position in the market with a share of 58% in 2025, owing to the rapid adoption of digital health, remote monitoring, and AI-driven care models. The integration of chronic care platforms with existing EHR systems simplifies workflows and facilitates better care coordination across different healthcare settings.
The services segment held a 42% share of the market in 2025, due to the increasing replacement of labor-intensive services. The transition from traditional fee-for-service models to value-based care has increased the need for expert consulting. The growing global burden of chronic diseases and the rising need for technical support and training.
Why Did the Healthcare Providers Segment Lead the Chronic Disease Management Market?
The healthcare providers segment registered its dominance over the market with a share of 64% in 2025, owing to the primary point of care and major adopters of management solutions. Increasing use of electronic health records, remote patient monitoring devices, and telehealth solutions has increased the reliance on provider-driven management systems.
The healthcare payers segment held the 36% share of the market in 2025, with the gaining influence as payers increasingly invest in preventive care and cost-control programs. Rising prevalence of economic burden and shift toward value-based care models, which incentivize investments in technologies that offer better clinical outcomes at lower costs.
Why Did the Cardiovascular Diseases Segment Lead the Chronic Disease Management Market?
The cardiovascular diseases segment registered its dominance over the market with a share of 28% in 2025, due to the highest global prevalence and high mortality risk. The growing adoption of AI-powered analytics and cloud-based platforms for managing heart patients remotely has optimized workflows and improved patient adherence, bolstering market growth.
The diabetes segment held the 24% share of the market in 2025, with the rapidly increasing global diabetic population. High adoption of continuous glucose monitoring systems, rising need for continuous monitoring. Governments are increasingly supporting healthcare digitalization and patient-centered care, which boosts the adoption of diabetes management devices.
The chronic obstructive pulmonary disorders segment held the 16% share of the market in 2025, with the rising pollution, smoking, and aging demographics. The development of novel inhaled therapies and combination therapies effectively manages symptoms and reduces severe exacerbations. The rising telemedicine and remote patient monitoring devices, and significant investment in the pharmaceutical industry.
The arthritis segment held the 14% share of the market in 2025, with the comparatively lower urgency and slower innovation in management solutions. The rising obesity rates and sedentary lifestyles have increased the prevalence of osteoarthritis, and advancements in therapeutics and biologics.
The others segment held the 18% share of the market in 2025, due to the diverse disease coverage but fragmented demand. Expansion of home health and long-term care, rising need for specialized care services, and a shift towards value-based care.
Why Did the North America Region Lead the Chronic Disease Management Market?
The North America region registered its dominance over the market with a share of 38% in 2025, owing to the high healthcare spending, infrastructure, and early technology adoption. The region's strong precision of healthcare technology companies, fueling innovation in AI-based analytics, remote patient monitoring, and telehealth, particularly in this region.
The Europe region held the 26% share of the market in 2025, with universal healthcare and steady digital transformation. It is a leader in adopting remote patient monitoring, telehealth, and AI-driven analytics, largely spurred by a need to improve efficiency and reduce hospitalization costs.
The Asia Pacific segment held 22% share of the market in 2025, due to the large population, rising chronic disease burden, and digital expansion. Growing shift towards cost-effective care and improved patient engagement solutions, and growing economies and higher disposable incomes in the region are fueling demand for better healthcare services.
The Latin America region held 8% share of the market in 2025, with limited healthcare funding but gradually expanding. The rising aging population has increased the need for long-term health and personal care services, putting pressure on existing infrastructure and driving investment.
The MEA region held 6% share of the market in 2025, due to the infrastructure gaps, though growth potential exists long-term. The robust government investment in the GCC and advanced hospital infrastructure, the market is pivoting from reactive treatment to proactive, data-driven population health management.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the chronic disease management market.
By Type
By End-user
By Disease Type
By Region
Chronic Disease Management Market
Download Sample
Request Customization
Request Customization
Download Sample